|Day Low/High||183.66 / 185.86|
|52 Wk Low/High||147.60 / 231.32|
Why Trump is killing biotech stocks, the Shire-for-Radius rumor makes no sense and Bernie Sanders gets a tweeting lesson.
-- Results from the National Eye C.A.R.E. Survey reinforce potential link between tech-dependency and growing risk of dry eye disease
Given the biotech's growth prospects and pipeline assets, its shares seem greatly undervalued.
Approval follows positive data from clinical studies on efficacy and tolerability, as well as infusion time and number of injection sites
The Consumer Union is alleging that Mylan may have paid Teva to withhold its EpiPen competitor from the market.
When it comes to investing in health care, hedge fund pro John Paulson knows his stuff.
- Xiidra is the only prescription eye drop approved by the U.S. FDA for the treatment of both signs and symptoms of dry eye disease
Stocks fluctuate on Monday as doubts over a production freeze agreement from major oil-producing countries snapped crude oil's recent rally.
Hedge fund managers continue to flee stocks in the second quarter, but the smart money eyed several potential opportunities, including Charter Communications and Morgan Stanley.
If they're underperforming, they're typically a precursor to a market correction.
The drug maker with an osteoporosis product in development has been speculated about as a consolidation candidate.
VONVENDI [von Willebrand factor (Recombinant)] is a significant advancement for the treatment of adults with von Willebrand disease (VWD)
Here are Thursday's top research calls, including downgrades for Tableau Data, Garmin and Pioneer Natural Resources, and an upgrade for Chegg.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMED, CGNX, CHGG, ENSG, FOMX, GATX, MIC, RPAI, SBRA, TDC, TSRI, TX, TZOO, WNRL Downgrades: AMIC, FE, SHPG, SOHU, TCBI Initiations: GPP Read on to get TheStreet Quant Ratings' detailed report:
Trade-Ideas LLC identified Shire (SHPG) as an unusual social activity candidate
The Ireland-based biopharma company lifts its forecast for Baxalta-related cost savings.